Quantification and Characterization of Human Endothelial Cell–Derived Tissue Factor Pathway Inhibitor-2

From the Department of Pathology (M.I., W.K.), University of New Mexico School of Medicine, Albuquerque, NM, and ZymoGenetics, Inc (D.C.F.), Seattle, Wash.

Correspondence to Dr Walter Kisiel, Department of Pathology, University of New Mexico School of Medicine, Albuquerque, NM 87131-5301.

Abstract—Tissue factor pathway inhibitor-2 (TFPI-2), also known as placental protein 5, is a serine protease inhibitor consisting of three tandemly-arranged Kunitz-type protease inhibitor domains. While TFPI-2 is a potent inhibitor of trypsin, plasmin, kallikrein, and factor XIa in the test tube, the function of this inhibitor in vivo remains unclear. In the present study, we investigated the synthesis and secretion of TFPI-2 by cultured endothelial cells derived from human umbilical vein, aorta, saphenous vein, and dermal microvessels to gain insight into its biological function. While all endothelial cells examined synthesized and secreted TFPI-2, dermal microvascular endothelial cells synthesized threefold to sevenfold higher levels of TFPI-2. Approximately 60% to 90% of the TFPI-2 secreted by endothelial cells was directed to the subendothelial extracellular matrix (ECM). When cultured human umbilical vein endothelial cells were stimulated with inflammatory mediators such as phorbol 12-myristate,13-acetate; endotoxin; and tumor necrosis factor-, TFPI-2 synthesis by these cells increased twofold to 14-fold. Recombinant TFPI-2 bound to dermal microvascular endothelial cell monolayers and its ECM in a specific, dose-dependent, and saturable manner with K_d values of 21 and 24 nmol/L, respectively. TFPI-2 interacted with 4.5x10¹⁰ sites/cm² (3x10⁵ sites/cell) and 2.3x10¹¹ sites/cm² on endothelial cells and ECM, respectively. In the presence of rabbit anti–TFPI-2 IgG, but not preimmune IgG, endothelial cells dissociated from the culture flask in a time- and IgG concentration–dependent manner. Our findings provide evidence that endothelial cell–derived TFPI-2 is primarily secreted into the abluminal space and presumably plays an important role in maintaining the integrity of the ECM essential for cell attachment.

Key Words: tissue factor pathway inhibitor-2 • endothelial cell • extracellular matrix • proteoglycan

This article has been cited by other articles:

				J. George, C. S. Gondi, D. H. Dinh, M. Gujrati, and J. S. Rao Restoration of Tissue Factor Pathway Inhibitor-2 in a Human Glioblastoma Cell Line Triggers Caspase-Mediated Pathway and Apoptosis Clin. Cancer Res., June 15, 2007; 13(12): 3507 - 3517. [Abstract] [Full Text] [PDF]

				L. Ivanciu, R. D. Gerard, H. Tang, F. Lupu, and C. Lupu Adenovirus-Mediated Expression of Tissue Factor Pathway Inhibitor-2 Inhibits Endothelial Cell Migration and Angiogenesis Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 310 - 316. [Abstract] [Full Text] [PDF]

				Z. Xu, D. Maiti, W. Kisiel, and E. J. Duh Tissue Factor Pathway Inhibitor-2 Is Upregulated by Vascular Endothelial Growth Factor and Suppresses Growth Factor-Induced Proliferation of Endothelial Cells Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2819 - 2825. [Abstract] [Full Text] [PDF]

				A. X. Torres-Collado, W. Kisiel, M. L. Iruela-Arispe, and J. C. Rodriguez-Manzaneque ADAMTS1 Interacts with, Cleaves, and Modifies the Extracellular Location of the Matrix Inhibitor Tissue Factor Pathway Inhibitor-2 J. Biol. Chem., June 30, 2006; 281(26): 17827 - 17837. [Abstract] [Full Text] [PDF]

				A. E. Schmidt, H. S. Chand, D. Cascio, W. Kisiel, and S. P. Bajaj Crystal Structure of Kunitz Domain 1 (KD1) of Tissue Factor Pathway Inhibitor-2 in Complex with Trypsin: IMPLICATIONS FOR KD1 SPECIFICITY OF INHIBITION J. Biol. Chem., July 29, 2005; 280(30): 27832 - 27838. [Abstract] [Full Text] [PDF]

				S. Scaife, R. Brown, S. Kellie, A. Filer, S. Martin, A. M. C. Thomas, P. F. Bradfield, N. Amft, M. Salmon, and C. D. Buckley Detection of differentially expressed genes in synovial fibroblasts by restriction fragment differential display Rheumatology, November 1, 2004; 43(11): 1346 - 1352. [Abstract] [Full Text] [PDF]

				H. S. Chand, A. E. Schmidt, S. P. Bajaj, and W. Kisiel Structure-Function Analysis of the Reactive Site in the First Kunitz-type Domain of Human Tissue Factor Pathway Inhibitor-2 J. Biol. Chem., April 23, 2004; 279(17): 17500 - 17507. [Abstract] [Full Text] [PDF]

				H. S. Chand, X. Du, D. Ma, H. D. Inzunza, S. Kamei, D. Foster, S. Brodie, and W. Kisiel The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice Blood, February 1, 2004; 103(3): 1069 - 1077. [Abstract] [Full Text] [PDF]

				W. Ruf, E. A. Seftor, R. J. Petrovan, R. M. Weiss, L. M. Gruman, N. V. Margaryan, R. E. B. Seftor, Y. Miyagi, and M. J. C. Hendrix Differential Role of Tissue Factor Pathway Inhibitors 1 and 2 in Melanoma Vasculogenic Mimicry Cancer Res., September 1, 2003; 63(17): 5381 - 5389. [Abstract] [Full Text] [PDF]

				C. Kast, M. Wang, and M. Whiteway The ERK/MAPK Pathway Regulates the Activity of the Human Tissue Factor Pathway Inhibitor-2 Promoter J. Biol. Chem., February 21, 2003; 278(9): 6787 - 6794. [Abstract] [Full Text] [PDF]

				J. T.B. Crawley, D. A. Goulding, V. Ferreira, N. J. Severs, and F. Lupu Expression and Localization of Tissue Factor Pathway Inhibitor-2 in Normal and Atherosclerotic Human Vessels Arterioscler Thromb Vasc Biol, February 1, 2002; 22(2): 218 - 224. [Abstract] [Full Text] [PDF]

				J. Kahn, F. Mehraban, G. Ingle, X. Xin, J. E. Bryant, G. Vehar, J. Schoenfeld, C. J. Grimaldi, F. Peale, A. Draksharapu, et al. Gene Expression Profiling in an in Vitro Model of Angiogenesis Am. J. Pathol., June 1, 2000; 156(6): 1887 - 1900. [Abstract] [Full Text] [PDF]

				U. R. Pendurthi, L. V. M. Rao, J. T. Williams, and S. Idell Regulation of Tissue Factor Pathway Inhibitor Expression in Smooth Muscle Cells Blood, July 15, 1999; 94(2): 579 - 586. [Abstract] [Full Text] [PDF]

				V. Neaud, T. Hisaka, A. Monvoisin, C. Bedin, C. Balabaud, D. C. Foster, A. Desmouliere, W. Kisiel, and J. Rosenbaum Paradoxical Pro-invasive Effect of the Serine Proteinase Inhibitor Tissue Factor Pathway Inhibitor-2 on Human Hepatocellular Carcinoma Cells J. Biol. Chem., November 3, 2000; 275(45): 35565 - 35569. [Abstract] [Full Text] [PDF]